Biomarin 投资 6000 万欧元扩建其科克工厂，促进遗传疾病药物的生产。 Biomarin invests €60 million to expand its Cork facility, boosting genetic disorder drug production.

生物技术公司Biomarin正在投资6 000万欧元,以扩大其爱尔兰Cork设施,并增设一个新的四层实验室,以促进其基因紊乱治疗的生产。 Biotechnology firm Biomarin is investing €60 million to expand its Cork, Ireland facility, adding a new four-story laboratory to boost production of its genetic disorder treatments. 这种扩大突出了爱尔兰在生物制药业中的重要性,是继先前加强该场址制造能力的投资之后进行的。 This expansion underscores Ireland's importance in biopharmaceuticals and follows a previous investment that enhanced the site's manufacturing capabilities. Cork设施是Biomarin在美国境外的唯一地点,现在雇用500多人。 The Cork facility, Biomarin's only site outside the U.S., now employs over 500 people.